TYK1 Inhibitors
1 drugsAbout TYK1
TYK1, or Tyrosine Kinase 1, is a protein kinase that regulates cellular processes by adding phosphate groups to proteins. Its dysregulation is often implicated in disease, making it a relevant target for therapeutic intervention.
Currently, there is no genetic evidence directly linking TYK1 to specific diseases, which increases the risk of target selection.
There is one FDA-approved drug, LORBRENA (Pfizer), targeting TYK1 as a small molecule for oncology indications. LORBRENA was first approved in 2018.
Top TYK1 Drugs
Pfizer is the only company with an approved drug targeting TYK1.
The limited number of companies indicates a high barrier to entry or untapped market potential.
TYK1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets TYK1, using small molecule modality.
Exploring alternative modalities like antibodies or PROTACs could provide a competitive advantage.
TYK1 Clinical Trials 36 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on TYK1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 12 | 6 | 3 | 3 | 67% |
| Phase 2 | 16 | 3 | 3 | 10 | 50% |
| Phase 3 | 3 | 0 | 0 | 3 | - |
| Phase 4 | 5 | 2 | 0 | 3 | 100% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
TYK1 Drug Approval Timeline (2018 - 2018)
LORBRENA was the first and only drug approved in 2018.
The single approval suggests the field is still nascent, offering opportunities for follow-on innovation.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 23 (5 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on TYK1. A trial counts if an approved drug acting on TYK1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.